Louis EJ, et al. - An inquiry was set up with regard to the impact of adalimumab therapy on extraintestinal manifestations (EIMs) resolution in patients with Crohn’s disease (CD). Researchers also intended to determine the potential predictors of EIM resolution in adult and pediatric patients with moderate to severe CD. They discovered that adalimumab was effective for achieving initial and durable resolution of any EIM and, in particular, arthritis/arthralgia in these patients. Adalimumab treatment and moderate disease severity served as the predictors of EIM resolution.